

**Pediatric Disease Working Party Educational Course on
"Sickle Cell Disease" 2019, Regensburg
(16.5.- 17. 5.2019)**



Thursday, 16.05.19

11:30 – 12:30 Lunch & Registration

Thursday, 16.05.19 Session 1: 13:00 – 15:10

Session Chairs: Krishnamurti Lakshmanan & Josu de la Fuente

12:45 – 13:00	Welcome Reception
13:00 – 13:20	Miguel Abboud An update on conventional therapy Beirut, Lebanon
13:20 – 13:40	Paul Telfer Medical treatments available for non-cerebrovascular complications London, UK
13:40 – 14:10	Francoise Bernaudin Management of cerebral vasculopathy in patient with sickle cell anemia? Paris, France
14:10 – 14:30	Julie Makani Approaches in developing countries Daressalam, Tanzania
14:30 – 14:50	Mahmoud Aljurf HSCT for Patients with Sickle Cell Disease in the Eastern Mediterranean Riadh, Saudi Arabia
14:50 – 15:10	Lawrence Faulkner How to setup a successful transplant program for hemoglobinopathies in developing countries: The Cure2Children approach Florence, Italy

15:10 – 15:50 Coffee Break

**Pediatric Disease Working Party Educational Course on
"Sickle Cell Disease" 2019, Regensburg
(16.5.- 17. 5.2019)**



Thursday, 16.05.19 Session 2: 15:50 – 18:30

Session Chairs: Miguel Abboud & Lawrence Faulkner

15:50 – 16:10	Krishnamurti Lakshmanan Should young children without severe disease with a matched sibling be offered BMT? <i>Atlanta, USA</i>
16:10 – 16:30	Josu de la Fuente Should children/young adult with non-severe disease be offered an alternative donor HSCT? <i>London, UK</i>
16:30 – 16:50	Pietro Sodani Is a matched unrelated donor equivalent to a matched sibling donor for a transplantation of SCD patients? <i>Berlin, Germany</i>
16:50 – 18:30	Round Table Discussion <ul style="list-style-type: none">• Can optimal conventional care provide a long-term cure?• To transplant or not to transplant: What are the minimal SCD related complications to offer a HSCT in 2019?• Would we still make differences between donor choice?• Is there an optimal conditioning or how much conditioning do we need?• Et al

20:00 - 23:00 Social Dinner

**Pediatric Disease Working Party Educational Course on
"Sickle Cell Disease" 2019, Regensburg**
(16.5.- 17. 5.2019)



Friday, 17.05.19 Session 3: 08:30 – 10:10

Session Chairs: John Tisdale & Fabio Ciceri

08:30 – 08:55	Jean-Hugues Dalle Hematologists and transplant physicians: Where do we meet? <i>Paris, France</i>
08:55 – 09:20	Eliane Gluckman Alternative donor hematopoietic stem cell transplantation for sickle cell disease in Europe. <i>Monaco, Montecarlo</i>
09:20 – 09:45	Adetola Kassim Alternative Donor: Post-Transplant Cyclophosphamide <i>Nashville, USA</i>
09:45 – 10:10	Selim Corbacioglu Alternative Donor: αβ/CD3 T-cell depleted Haplo HSCT <i>Regensburg, Germany</i>

10:10 – 10:40 Coffee Break

Friday, 17.05.19 Session 4: 10:40 - 11:55

Session Chairs: Eliane Gluckman, Julie Makani

10:40 – 11:05	Lisa Oostenbrink What is the impact of ATG Pharmacokinetic on haploidentical HSCT in SCD? <i>Leiden, Netherlands</i>
11:05 – 11:30	Marta Palomo Is sickle cell disease related NT a systemic endotheliopathy? <i>Barcelona, Spain</i>
11:30 – 11:55	Adetola Kassim Oxygen extraction in SCD? <i>Nashville, USA</i>

12:00 – 13:00 Lunch Symposium kindly supported by Jazz Pharmaceuticals
Managing Endothelial Post-Transplant Complications in SCD

**Pediatric Disease Working Party Educational Course on
"Sickle Cell Disease" 2019, Regensburg
(16.5.- 17. 5.2019)**



Friday, 17.05.19 Session 5: 13:00 – 16:30

Session Chairs: Mahmoud Aljurf & Adetola Kassim

13:00 – 13:25	Laure Joseph Gene Therapy for S/S, where do we stand? Paris, France
13:25 – 13:50	John Tisdale Gene Therapy: Lentiviral gene therapy, Update of the BluebirdBio Approach Washington, USA
13:50 – 14:15	David Williams Gene Therapy: BCL11A as a Therapeutic Target in Gene Therapy for Sickle Cell Disease Boston, USA
14:15 – 14:40	Fabio Ciceri Gene Therapy: Hematopoietic stem cell lentiviral gene therapy for adult and pediatric patients affected by hemoglobinopathies: the Milano experience Milan, Italy
14:40 – 15:05	NN (Rupert/Josu/Selim) Gene Therapy: CrispRCas based Gene Therapy for Hemoglobin Germany/UK
15:05 – 16:30	Round Table Discussion <ul style="list-style-type: none">• Pro's and Con's: gene therapy vs. HSCT?• Is there an upper or lower age limit for gene therapy or HSCT?• What are the pro's and con's of the different gene therapeutic approaches?• Et al